HAEMONETICS CORP — Director's Dealing 2011

Oct 27, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2011-10-25

Reporting Person: White Jonathan (VP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-10-25	Common Stock	A	1955.0	$0.01	Acquired	10679.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-10-25	Non-Qualified Stock Option (right to buy)	$61.34	A	17565.0	Acquired	2018-10-25	Common Stock (17565.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1500.0	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$52.94	2016-10-27	Common Stock (12242.0)	12242.0	Direct
Non-Qualified Stock Option (right to buy)	$54.99	2017-10-27	Common Stock (15388.0)	15388.0	Direct
Non-Qualified Stock Option (right to buy)	$60.05	2016-01-28	Common Stock (17641.0)	17641.0	Direct
Non-Qualified Stock Option (right to buy)	$67.85	2018-07-20	Common Stock (13974.0)	13974.0	Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.